Pharmaceutical and nutraceutical compositions of abscisic acid
View Patent ↗The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of pharmaceutical and/or nutraceutical use.
1. A method of decreasing triglyceride levels in blood comprising administering to a patient a therapeutically effective amount of: i) abscisic acid; ii) a compound of structure 1
wherein R 1 is selected form the group consisting of ethynyl, ethenyl, cyclopropyl, and trifluoromethyl, R 2 is selected from the group consisting of hydrogen and a lower alkyl, and R 1 is in a cis-relationship to the alcoholic hydroxyl group;
a compound of structure 2
wherein R 1 is selected from the group consisting of hydrogen and a lower alkyl; or
a compound of structure 3
wherein R 1 is selected from the group consisting of hydrogen and a lower alkyl;
wherein a cis- or trans-double bond is at a 2 nd position of a side chain, a trans-double bond or a triple bond is at a 4 th position of the side chain, the alcoholic hydroxyl groups have S-, R- or an R,S-mixture stereochemistry, and the lower alkyl is an alkyl group containing 1 to 4 carbon atoms in a straight or branched chain; or
iii) isomeric forms, racemic mixtures, enol forms, solvated forms, unsolvated forms, prodrugs, ester derivatives, ether derivatives, or salts thereof,
wherein the therapeutically effective amount is from about 0.1 mg/kg/day to about 1000 mg/kg/day.
2. A method of reducing glucose levels comprising administering to a patient in need thereof a therapeutically effective amount of: i) abscisic acid; ii) a compound of structure 1
wherein R 1 is selected form the group consisting of ethynyl, ethenyl, cyclopropyl, and trifluoromethyl, R 2 is selected from the group consisting of hydrogen and a lower alkyl, and R 1 is in a cis-relationship to the alcoholic hydroxyl group;
a compound of structure 2
wherein R 1 is selected from the group consisting of hydrogen and a lower alkyl; or
a compound of structure 3
wherein R 1 is selected from the group consisting of hydrogen and a lower alkyl;
wherein a cis- or trans-double bond is at a 2 nd position of a side chain, a trans-double bond or a triple bond is at a 4 th position of the side chain, the alcoholic hydroxyl groups have S-, R- or an R,S-mixture stereochemistry, and the lower alkyl is an alkyl group containing 1 to 4 carbon atoms in a straight or branched chain; or
iii) isomeric forms, racemic mixtures, enol forms, solvated forms, unsolvated forms, prodrugs, ester derivatives, ether derivatives, or salts thereof,
wherein the therapeutically effective amount is from about 0.1 mg/kg/day to about 1000 mg/kg/day.
3. An infant formula composition comprising from about 0.5% to about 50% by weight of: i) abscisic acid; ii) a compound of structure 1
wherein R 1 is selected form the group consisting of ethynyl, ethenyl, cyclopropyl, and trifluoromethyl, R 2 is selected from the group consisting of hydrogen and a lower alkyl, and R 1 is in a cis-relationship to the alcoholic hydroxyl group;
a compound of structure 2
wherein R 1 is selected from the group consisting of hydrogen and a lower alkyl; or
a compound of structure 3
wherein R 1 is selected from the group consisting of hydrogen and a lower alkyl;
wherein a cis- or trans-double bond is at a 2 nd position of a side chain, a trans-double bond or a triple bond is at a 4 th position of the side chain, the alcoholic hydroxyl groups have S-, R- or an R,S-mixture stereochemistry, and the lower alkyl is an alkyl group containing 1 to 4 carbon atoms in a straight or branched chain; or
iii) isomeric forms, racemic mixtures, enol forms, solvated forms, unsolvated forms, prodrugs, ester derivatives, ether derivatives, or salts thereof.
4. A nutritional composition for administration to a patient comprising from about 0.5% to about 50% by weight of: i) abscisic acid; ii) a compound of structure 1
wherein R 1 is selected form the group consisting of ethynyl, ethenyl, cyclopropyl, and trifluoromethyl, R 2 is selected from the group consisting of hydrogen and a lower alkyl, and R 1 is in a cis-relationship to the alcoholic hydroxyl group;
a compound of structure 2
wherein R 1 is selected from the group consisting of hydrogen and a lower alkyl; or
a compound of structure 3
wherein R 1 is selected from the group consisting of hydrogen and a lower alkyl;
wherein a cis- or trans-double bond is at a 2 nd position of a side chain, a trans-double bond or a triple bond is at a 4 th position of the side chain, the alcoholic hydroxyl groups have S-, R- or an R,S-mixture stereochemistry, and the lower alkyl is an alkyl group containing 1 to 4 carbon atoms in a straight or branched chain; or
iii) isomeric forms, racemic mixtures, enol forms, solvated forms, unsolvated forms, prodrugs, ester derivatives, ether derivatives, or salts thereof.
5. A food ingredient for consumption comprising from about 0.5% to about 50% by weight of: i) abscisic acid; ii) a compound of structure 1
wherein R 1 is selected form the group consisting of ethynyl, ethenyl, cyclopropyl, and trifluoromethyl, R 2 is selected from the group consisting of hydrogen and a lower alkyl, and R 1 is in a cis-relationship to the alcoholic hydroxyl group;
a compound of structure 2
wherein R 1 is selected from the group consisting of hydrogen and a lower alkyl; or
a compound of structure 3
wherein R 1 is selected from the group consisting of hydrogen and a lower alkyl;
wherein a cis- or trans-double bond is at a 2 nd position of a side chain, a trans-double bond or a triple bond is at a 4 th position of the side chain, the alcoholic hydroxyl groups have S-, R- or an R,S-mixture stereochemistry, and the lower alkyl is an alkyl group containing 1 to 4 carbon atoms in a straight or branched chain; or
iii) isomeric forms, racemic mixtures, enol forms, solvated forms, unsolvated forms, prodrugs, ester derivatives, ether derivatives, or salts thereof.
6. The method of claim 1 wherein the therapeutically effective amount is from about 10 mg/kg/day to about 1000 mg/kg/day.
7. The method of claim 1 wherein the therapeutically effective amount is from about 50 mg/kg/day to about 500 mg/kg/day.
8. The method of claim 1 wherein the therapeutically effective amount is from about 50 mg/kg/day to about 200 mg/kg/day.
9. The method of claim 1 comprising S-abscisic acid.
10. The method of claim 2 wherein the therapeutically effective amount is from about 10 mg/kg/day to about 1000 mg/kg/day.
11. The method of claim 2 wherein the therapeutically effective amount is from about 50 mg/kg/day to about 500 mg/kg/day.
12. The method of claim 2 wherein the therapeutically effective amount is from about 50 mg/kg/day to about 200 mg/kg/day.
13. The method of claim 2 comprising S-abscisic acid.